Cero Therapeutics Holdings, Inc. financial data

Symbol
PBAX, PBAXU, PBAXW on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
201 Haskins Way, Suite 230, South San Francisco, California
State of incorporation
Delaware
Fiscal year end
December 31
Former names
PHOENIX BIOTECH ACQUISITION CORP. (to 2/14/2024)
Latest financial report
Q1 2024 - May 17, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 141 %
Debt-to-equity -62.4 % +65.4%
Return On Equity 22.3 % -18.7%
Return On Assets -44.3 % -1593%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 14.7 M shares
Common Stock, Shares, Outstanding 9.07 M shares
Entity Public Float 2.69 M USD -98.5%
Common Stock, Value, Issued 907 USD +931%
Weighted Average Number of Shares Outstanding, Basic 14.1 M shares +55.8%
Weighted Average Number of Shares Outstanding, Diluted 14.1 M shares +55.8%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 904 K USD -49.8%
General and Administrative Expense 4.84 M USD +54.7%
Operating Income (Loss) -6.53 M USD -49.9%
Nonoperating Income (Expense) 1.93 M USD +12046488%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -308 K USD -313%
Income Tax Expense (Benefit) 25.8 K USD -57.4%
Net Income (Loss) Attributable to Parent -4.07 M USD -49.2%
Earnings Per Share, Basic -0.12 USD/shares +55.6%
Earnings Per Share, Diluted -0.12 USD/shares +55.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 96.9 K USD -79.6%
Assets, Current 5.5 M USD
Property, Plant and Equipment, Net 853 K USD
Operating Lease, Right-of-Use Asset 2.02 M USD
Assets 9.05 M USD -37.3%
Accounts Payable, Current 7.06 M USD
Employee-related Liabilities, Current 123 K USD
Accrued Liabilities, Current 294 K USD
Liabilities, Current 11.7 M USD +254%
Operating Lease, Liability, Noncurrent 1.37 M USD
Liabilities 13 M USD +4.73%
Retained Earnings (Accumulated Deficit) -64.9 M USD
Stockholders' Equity Attributable to Parent -3.98 M USD +65.6%
Liabilities and Equity 9.05 M USD -37.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -198 K USD +35.8%
Net Cash Provided by (Used in) Investing Activities -100 K USD
Common Stock, Shares Authorized 45.4 M shares
Common Stock, Shares, Issued 9.07 M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -298 K USD +3.35%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 4.59 M USD +2479%
Deferred Tax Assets, Valuation Allowance 608 K USD +1.81%
Cash and Cash Equivalents, Period Increase (Decrease) -308 K USD
Deferred Tax Assets, Gross 608 K USD +1.81%
Operating Lease, Liability 2.16 M USD
Depreciation 37.4 K USD
Lessee, Operating Lease, Liability, to be Paid 2.44 M USD
Operating Lease, Liability, Current 795 K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 726 K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 990 K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 278 K USD
Preferred Stock, Shares Issued 4 M shares
Deferred Federal Income Tax Expense (Benefit) 182 K USD
Preferred Stock, Shares Authorized 1 M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 54 M USD
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 90 K USD +220%
Interest Expense 14.4 K USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%